Shares of ADMA Biologics Inc. (ADMA) were down over 30% in extended trading on Friday, following the receipt of FDA's Complete Response Letter for RI-002, an intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency Disease.
from RTT - Biotech http://ift.tt/2aHCciX
via IFTTT
No comments:
Post a Comment